FEDER - CNRS - API
Kohesio
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Over the last twenty years, the production of intermediates or pharmaceutical active ingredients - most of which have fallen into the public domain - has been overwhelmingly outsourced to Asian countries for cost reasons intrinsically linked to the batch production method of these compounds. Indeed, the use of batch reactors means that to produce more you necessarily need reactors of greater capacity, and therefore very high investment costs, leading to the dismantling of the pharmaceutical production tool in France and Europe. However, today there is an alternative to this batch production: portable flow reactors. Where traditional batch production requires very large installations, flow synthesis uses a production tool the size of a household appliance. This “miniature factory” is both modular and mobile, allowing different pharmaceutical principles to be prepared on different sites according to local needs. In addition, such systems offer an innovative link between chemical synthesis and the design of autonomous factories. While flow chemical synthesis is booming on the international scene (MIT, Cambridge, Graz, Montreal and Kyoto), it still lacks visibility in France. It is in this context that the COBRA UMR 6014 laboratory has established itself as an emerging national player, and today wishes to use the expertise of its teams to initiate in the Normandy Region an ambitious research program dedicated to the pharmaceutical independence of the Normandy territory and transposable to the national scale: the ‘Pharmaceutical and Industrial Autonomy’ (API) project.
Smarter Europe / Research and innovation / Research and innovation activities in public research centres and centres of competence including networking